ALLR Allarity Therapeutics (ALLR) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001860657
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
11
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · no price filed
Allarity Therapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for Allarity Therapeutics, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
no insider purchases or sales on record
0 transactions on record
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
11 funds bought in last quarter
below 80% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
$262.0K repurchased, FY to 2026-06-30
below 93% of Pharma & Biotech
Short interest
1.1% of the float short (float per yahoo 2026-10-27) · 1.4 days to cover · settled 2026-10-15
below 72% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch ALLR
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-33.8%12M
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns ALLR: institutional holders (13F)
13F holdings, latest reported quarter
331,509 sh
$427.6K
171,795 sh
$221.6K
154,867 sh
$199.8K
137,600 sh
$177.5K
98,978 sh
$127.7K
Congress trades in ALLR
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
ALLR planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
ALLR mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$154.6K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$221.6K position · as of 2026-06-30
0.0%
Fidelity Series Total Market Index Fund
$35.4K position · as of 2026-05-31
0.0%
Fidelity Total Market Index Fund
$36.4K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
6 registered trials, 2 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 1
0 active
4
Phase 2
1 active
1
Not applicable
1 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 11 funds added last quarter. Each figure is a federal filing, dated the day it went public.
ALLR financials
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Revenue, TTM ALLR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | $0 |
| Mar 2026 | $25.0K |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | $0 |
| Mar 2025 | $0 |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Net margin, TTM ALLR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
capex not filed for the four quarters
Free cash flow, TTM ALLR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -$2.6M |
| Mar 2026 | -$4.6M |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | -$5.5M |
| Mar 2025 | -$2.7M |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Debt to equity
6.66x
long-term 2023-12-31 (30 months older than the period end) plus current 2026-06-30; equity 2026-06-30
Debt to equity ALLR
| FY Dec 2025 | 0.27x |
| FY Dec 2024 | 0.25x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 6.66x |
| Mar 2026 | 3.29x |
| Dec 2025 | 0.27x |
| Sep 2025 | 0.24x |
| Jun 2025 | 0.24x |
| Mar 2025 | 0.16x |
| Dec 2024 | 0.25x |
| Sep 2024 | 0.23x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-0.58x
TTM operating cash flow over long-term 2023-12-31 (30 months older than the period end) plus current 2026-06-30
Cash flow to debt ALLR
| FY Dec 2025 | -5.52x |
| FY Dec 2024 | -5.91x |
| FY Dec 2023 | -4.34x |
| FY Dec 2022 | -6.36x |
| FY Dec 2021 | n/a |
| Jun 2026 | -0.58x |
| Mar 2026 | -0.73x |
| Dec 2025 | -5.52x |
| Sep 2025 | -5.03x |
| Jun 2025 | -5.73x |
| Mar 2025 | -6.35x |
| Dec 2024 | -5.91x |
| Sep 2024 | -5.39x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-157.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity ALLR
| FY Dec 2025 | -103.8% |
| FY Dec 2024 | -541.2% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -178.0% |
| FY Dec 2021 | -125.1% |
| Jun 2026 | -157.1% |
| Mar 2026 | -87.9% |
| Dec 2025 | -103.8% |
| Sep 2025 | -122.6% |
| Jun 2025 | -150.6% |
| Mar 2025 | -383.7% |
| Dec 2024 | -541.2% |
| Sep 2024 | -391.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-46.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets ALLR
| FY Dec 2025 | -54.9% |
| FY Dec 2024 | -142.1% |
| FY Dec 2023 | -90.1% |
| FY Dec 2022 | -50.0% |
| FY Dec 2021 | -64.2% |
| Jun 2026 | -46.3% |
| Mar 2026 | -34.8% |
| Dec 2025 | -54.9% |
| Sep 2025 | -74.4% |
| Jun 2025 | -92.5% |
| Mar 2025 | -112.3% |
| Dec 2024 | -142.1% |
| Sep 2024 | -109.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital ALLR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-137.5%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed ALLR
| FY Dec 2025 | -116.5% |
| FY Dec 2024 | -573.1% |
| FY Dec 2023 | -3,369% |
| FY Dec 2022 | -213.8% |
| FY Dec 2021 | -93.5% |
| Jun 2026 | -137.5% |
| Mar 2026 | -95.8% |
| Dec 2025 | -116.5% |
| Sep 2025 | -136.2% |
| Jun 2025 | -165.3% |
| Mar 2025 | -412.3% |
| Dec 2024 | -573.1% |
| Sep 2024 | -447.1% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
P/E, trailing ALLR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$21.2M
market value at close 2026-10-27 on 2026-08-14 shares, plus long-term 2023-12-31 (30 months older than the period end) plus current 2026-06-30, minus cash 2026-06-30
Enterprise value ALLR
| FY Dec 2025 | $5.1M |
| FY Dec 2024 | -$11.4M |
| FY Dec 2023 | $1.5B |
| FY Dec 2022 | $2.5T |
| FY Dec 2021 | n/a |
| Jun 2026 | $27.1M |
| Mar 2026 | $20.2M |
| Dec 2025 | $5.1M |
| Sep 2025 | $9.1M |
| Jun 2025 | $366.4K |
| Mar 2025 | -$6.3M |
| Dec 2024 | -$11.4M |
| Sep 2024 | $73.1M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
capex not filed for the four quarters
FCF yield ALLR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
PEG, trailing ALLR
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $320.0K | $0 | n/a | n/a |
| Gross profit | n/a | n/a | n/a | -$2.3M |
| Operating income | -$12.6M | -$27.2M | -$17.1M | -$34.5M |
| Net income | -$11.2M | -$24.5M | -$11.9M | -$16.1M |
| EPS (diluted) | n/a | n/a | -10.26 | -3,093.42 |
| Operating cash flow | -$14.8M | -$17.4M | -$12.7M | -$16.8M |
| Cash | $14.7M | $19.5M | $166.0K | $2.0M |
| Long-term debt | n/a | n/a | $2.7M | $2.6M |
| Buybacks | $3.2M | $0 | n/a | n/a |
SEC XBRL, fiscal years, as known on 2026-10-28
ALLR Stock Sonar score 4/7 axes
Find similar shapesCompareALLR ranks highest on risk and compliance (91st percentile) and financial health (31st), and lowest on institutional and government (20th), among Pharma & Biotech peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
